Eli Lilly 2015 Annual Report Download - page 102

Download and view the complete annual report

Please find page 102 of the 2015 Eli Lilly annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 186

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186

F90
FINANCIAL REPORT
Reclassifications Out of Accumulated Other
Comprehensive Loss
Details about Accumulated Other
Comprehensive Loss Components
Year Ended December 31, Affected Line Item in the Consolidated
Statements of Operations2015 2014 2013
Amortization of defined benefit
items:
Prior service benefits, net $(80.7)$ (34.0) $ (31.9) (1)
Actuarial losses 421.2 303.0 515.2 (1)
Total before tax 340.5 269.0 483.3
Tax benefit (105.6) (83.4) (164.3) Income taxes
Net of tax 234.9 185.6 319.0
Unrealized gains/losses on
available-for-sale securities:
Realized gains, net (209.3)(324.1) (12.0) Other—net, (income) expense
Impairment losses 12.0 — 2.4 Other—net, (income) expense
Total before tax (197.3) (324.1) (9.6)
Tax expense 69.1 113.4 3.4 Income taxes
Net of tax (128.2) (210.7) (6.2)
Other, net of tax 9.5 5.9 5.9 Other—net, (income) expense
Total reclassifications for the
period (net of tax) $116.2 $ (19.2) $ 318.7
(1) These accumulated other comprehensive loss components are included in the computation of net periodic pension cost (see Note 14).
Note 17: Other–Net, (Income) Expense
Other–net, (income) expense consisted of the following:
2015 2014 2013
Income related to termination of the exenatide collaboration with
Amylin (Note 4) $ — $ — $ (495.4)
Interest expense 161.2 148.8 160.1
Interest income (87.0) (121.0) (119.7)
Debt extinguishment loss (Note 10) 166.7 — —
Other income (341.5) (368.3) (63.9)
Other–net, (income) expense $ (100.6) $ (340.5) $ (518.9)
For the year ended December 31, 2015, other income is primarily related to net gains on investments (Note
7). For the year ended December 31, 2014, other income is primarily related to net gains on investments
(Note 7) and income related to the transfer to Boehringer Ingelheim of our license rights to co-promote
linagliptin and empagliflozin in certain countries (Note 4).
Note 18: Segment Information
We operate in two business segments—human pharmaceutical products and animal health. Our business
segments are distinguished by the ultimate end user of the product—humans or animals. Performance is
evaluated based on profit or loss from operations before income taxes. The accounting policies of the
individual segments are the same as those described throughout the notes to the consolidated financial
statements.